Journal of Ophthalmology

Journal of Ophthalmology / 2018 / Article

Corrigendum | Open Access

Volume 2018 |Article ID 5047142 | https://doi.org/10.1155/2018/5047142

Lei Lu, Ying Jiang, Ravindran Jaganathan, Yanli Hao, "Corrigendum to “Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review”", Journal of Ophthalmology, vol. 2018, Article ID 5047142, 1 page, 2018. https://doi.org/10.1155/2018/5047142

Corrigendum to “Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review”

Received24 Jun 2018
Accepted24 Sep 2018
Published02 Dec 2018

In the article titled “Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review” [1], there was an error in the second and third affiliations. The corrected affiliations are shown above.

In the “4.2. Corticosteroid Therapy with Sustained Delivery System” subsection, the following should be updated:(1)The text reading “It has been reported by a FAME study that low dose of Iluvien inserted (0.19 mg per day) showed improved BCVA compared to higher dose [14, 15, 39]. Currently, Iluvien is still under investigation by FDA to approve its application to the market [13]” should be corrected to “It has been reported by a FAME study that low dose of Iluvien inserted (0.2 mg per day) showed improved BCVA compared to higher dose [14, 15, 39]. At 3 years in the FAME trials, Iluvien (0.2 µg fluocinolone acetonide per day) led to 28.7% of patients achieving a ≥15 letter score improvement in visual acuity versus 18.9% in the sham group. This effect was even greater in a preplanned analysis of the data assessing the impact in patients with persistent or recurrent diabetic macular edema (DME) and in this group Iluvien led to 34.0% achieving a ≥15 letter score improvement versus 13.4% in the sham group. Based on the results of the FAME pivotal trials, Iluvien is now approved for use in DME in Europe and the USA.”(2)The sentence reading “In comparison, another fluocinolone acetonide intravitreal implant, Retisert® (Bausch and Lomb), is approved by FDA for the treatment of chronic, noninfectious uveitis. However, its treatment caused severe cataract and glaucoma in a phase III clinical trial [14, 15]” should be removed.

References

  1. L. Lu, Y. Jiang, R. Jaganathan, and Y. Hao, “Current advances in pharmacotherapy and technology for diabetic retinopathy: a systematic review,” Journal of Ophthalmology, vol. 2018, Article ID 1694187, 13 pages, 2018. View at: Publisher Site | Google Scholar

Copyright © 2018 Lei Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views443
Downloads229
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.